Neumora Therapeutics is laying off about 35% of its workforce after its lead experimental depression drug, navacaprant, failed two Phase 3 trials (KOASTAL-2 and KOASTAL-3) in major depressive disorder. Sources: Neumora discards depression asset, lays off staffers after pair of late ... Neumora Therapeutics scraps depression drug after two late-stage trial failures Neumora scraps depression drug development after repeated trial ... Neumora to lay off 35% of staff after navacaprant goes 0 for 3 in late ... NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials Neumora Ends Depression Drug Programme and Announces ... Neumora Ends Phase 3 KOASTAL Study Of Navacaprant, To Lay Off 35% Of Workforce; Stock Plunges 50% Neumora Therapeutics Reports Data from Phase 3 KOASTAL ... Neumora Therapeutics (NMRA) Stocks News Today - Tickeron.com Neumora (Nasdaq: NMRA) ends navacaprant, cuts 35% of staff and ... Neum...
- Get link
- X
- Other Apps